Next Article in Journal
Generational Health Impact of PCOS on Women and Their Children
Previous Article in Journal
Neurorehabilitation of Traumatic Brain Injury (TBI): A Clinical Review
Open AccessArticle

Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California

1
Internal Medicine Residency Program, Kaiser Permanente, Santa Clara, CA, USA
2
Department of Drug Utilization, Kaiser Permanente, Oakland, CA 94612, USA
3
Department of Oncology and Hematology, Kaiser Permanente, Oakland, CA 95051, USA
4
Division of Research, Kaiser Permanente, Oakland, CA 94612, USA
*
Author to whom correspondence should be addressed.
Med. Sci. 2019, 7(3), 48; https://doi.org/10.3390/medsci7030048
Received: 16 January 2019 / Revised: 7 March 2019 / Accepted: 11 March 2019 / Published: 18 March 2019
(This article belongs to the Section Cancer and Cancer-Related Research)
Background: Pazopanib was approved for advanced soft tissue sarcoma as a second- or third-line therapy based on the clinical trial “Pazopanib for metastatic soft-tissue sarcoma” (PALETTE). We hypothesized that the real-world experiences may be significantly different from the clinical trial results. Methods: We analyzed the response pattern of patients with advanced soft tissue and bone sarcoma who received pazopanib treatment between 1 January 2011 and 31 October 2018 in Kaiser Permanente Northern California. Results: A total of 123 patients with 23 different histologic subtypes were assessable. One patient with low-grade fibromyxoid sarcoma obtained complete response (CR) after 2 months of treatment with pazopanib, 12 patients (9.7%) obtained partial response (PR), 34 patients (27.6%) had stable disease (SD), while 76 patients (61.8%) developed progressive disease (PD). The disease control rate (DCR) was 46.3% (CR + PR + SD). Among the 12 patients with PR, 3 had undifferentiated pleomorphic sarcoma (UPS), 4 had leiomyosarcoma (LMS), 2 had pleomorphic rhabdomyosarcoma, 1 had pleomorphic liposarcoma, 1 had dedifferentiated liposarcoma, and 1 had angiosarcoma. The median duration of response was 9 months. Two patients with Ewing’s sarcoma had SD for 6 and 13 months, and two patients with osteosarcoma had SD for 6 and 9 months. Among 65 patients assessed at 8 weeks, 9 had a response, and 10 had SD. Among 104 patients assessed at 12 weeks, 12 had a response, and 26 had SD. The median progression-free survival (PFS) was approximately 3 months for all 123 cases and for patients with UPS and LMS. Conclusions: Our cohort of patients with advanced soft tissue and bone sarcoma in Northern California treated with pazopanib had diverse histologic subtypes. The response rate (CR + PR) was higher than that of the PALETTE trial, while the DCR and the median PFS were significantly lower. The observation of PR in two patients with liposarcoma and durable SD in several patients with bone sarcoma indicates that pazopanib has activity in liposarcoma and bone sarcoma. View Full-Text
Keywords: pazopanib; soft tissue sarcoma; bone sarcoma; real-world experiences; complete response; partial response; disease control rate; progression-free survival pazopanib; soft tissue sarcoma; bone sarcoma; real-world experiences; complete response; partial response; disease control rate; progression-free survival
Show Figures

Figure 1

MDPI and ACS Style

Seto, T.; Song, M.-N.; Trieu, M.; Yu, J.; Sidhu, M.; Liu, C.-M.; Sam, D.; Pan, M. Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California. Med. Sci. 2019, 7, 48.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop